Videos
Industry-Sponsored Lecture (MSD)
Critical Decisions for Critical Patients: Management on Nosocomial Pneumonia in an Era of MDRO
Speakers:
Marin Hristo Kollef, MD, FACP, FCCP
Rontgene M. Solante, MD, FPCP, FPSMID
Videos
Industry-Sponsored Lecture (Pfizer)
Clinicians insights in the Management of Severe CAP, HAP and VAP
Speaker: Albert Rafanan, MD, FPCP, FPCCP
Videos
Industry-Sponsored Lecture (Pfizer)
Ceftaroline in Combating Community-Acquired Pneumonia (CAP)
Speaker: Alex Soriano, MD
Head of Infectious Diseases Department, Hospital Clinic
Assistant Professor, University of Barcelona
Clinical Practice Guidelines
Internationally, community-acquired pneumonia (CAP) remains the leading cause of death from an infectious disease. It is the sixth leading cause of death overall and is a major cause of morbidity and mortality. Since the last publication of Philippine Clinical Practice Guidelines on the Diagnosis, Empiric Management, and Prevention of Community-acquired Pneumonia (CAP) in Immunocompetent Adults in 2010, several changes had emerged:
Multiple international societies had published and revised their guidelines of the management of patients with CAP.
New organisms had emerged and development of resistance had increased over time among respiratory pathogens.
The influx and efflux of antimicrobial agents used in the treatment had likewise posed a threat to the rapid rise of antimicrobial resistance. The use, misuse, abuse and overuse had also shaken the market of antimicrobial agents.
It is for these reasons that a long overdue update on the management of CAP is needed. There is a need to standardize care by providing management strategies based on best available evidences. The evidences may be the same; however, regional differences, causative agents, antibiotic resistance rates, drug licensing, healthcare structure and available resources may vary. Recommendations made by one national organization may therefore not be applicable to other countries